Welcome to our dedicated page for Corbus Pharmaceu SEC filings (Ticker: CRBP), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Corbus Pharmaceuticals Holdings, Inc. (CRBP) SEC filings page on Stock Titan provides direct access to the company’s regulatory disclosures, along with AI-assisted context for key documents. Corbus is a clinical-stage oncology and obesity company, and its filings reflect the financial, clinical, and governance developments associated with advancing drug candidates such as CRB-701, CRB-601, and CRB-913.
Investors can review Form 8‑K current reports in which Corbus discloses material events, including quarterly financial results, preliminary cash and investment balances, Fast Track designations for CRB-701, and entry into material definitive agreements such as underwriting agreements for public offerings of common stock and pre-funded warrants. Certain 8‑K filings also describe board-level changes, such as the planned retirement of a director, and clarify that such departures are not due to disagreements over company operations or policies.
Quarterly and annual financial information referenced in 8‑K exhibits is complemented by the company’s full 10‑Q and 10‑K reports, which are accessible through EDGAR and summarized by Stock Titan’s AI tools. These reports typically include detailed discussions of research and development spending, net losses associated with clinical-stage operations, and liquidity and capital resources, including the impact of public offerings and at-the-market sales programs.
For users interested in insider and governance activity, Form 4 and related ownership filings, when available, can be used to track changes in beneficial ownership by directors and officers. Stock Titan’s platform surfaces new filings in near real time and applies AI-powered summaries to highlight the sections that matter most, such as clinical program updates, risk factor changes, and financing terms. This allows readers to navigate lengthy SEC documents more efficiently while still being able to drill down into the original filings for full detail.
CRBP insider filed a Form 144 to sell Common Stock. The notice lists proposed brokered sales through Stifel Nicolaus & Company and records Restricted Stock Units of 12,500 dated 02/28/2026. The filing also discloses a prior sale of 3,285 shares on 02/03/2026.
Corbus Pharmaceuticals Holdings furnished an updated investor presentation outlining its cash position, pipeline and upcoming milestones. The company reported $173M in cash, cash equivalents and investments as of November 3, 2025, with approximately 17 common shares issued and outstanding and about 20 fully diluted shares.
The presentation highlights three key programs. CRB-701, a next‑generation Nectin‑4 antibody–drug conjugate, showed objective response rates up to 47.6% in head and neck cancer and 55.6% in cervical cancer at the 3.6 mg/kg dose in early studies, with lower rates of peripheral neuropathy and rash than PADCEV in referenced datasets. CRB-913, a peripherally restricted CB1 inverse agonist for obesity, produced 2.9% placebo‑adjusted weight loss by day 14 in a 150 mg multiple‑dose cohort, with no reported nausea, vomiting or constipation in the summarized data.
CRB-601, an anti‑αvβ8 antibody targeting TGFβ activation in solid tumors, is in early clinical development. Corbus outlines planned milestones into 2026, including a Phase 2/3 registrational study for CRB‑701 in head and neck cancer, additional combination data with pembrolizumab, and completion of a 240‑patient Phase 1b obesity study for CRB‑913.
Corbus Pharmaceuticals Holdings, Inc.’s Chief Operating Officer Ian Hodgson reported an open-market sale of 847 shares of common stock at a weighted-average price of $7.383 per share. According to the disclosure, this sale was mandated as a “sell to cover” transaction to satisfy tax withholding obligations tied to the vesting and settlement of restricted stock units and was not a discretionary trade.
After the transaction, Hodgson directly held 51,080 shares, which the disclosure notes includes 46,362 unvested restricted stock units that continue to vest under their existing schedules.
Corbus Pharmaceuticals Holdings, Inc. Chief Financial Officer Sean F. Moran reported an open-market sale of 4,701 shares of common stock at a weighted average price of $7.783 per share. After this sale, he directly holds 96,694 shares, including 68,795 unvested restricted stock units.
The transaction was executed under a pre-arranged Rule 10b5-1 trading plan and was used to cover tax withholding obligations arising from the vesting and settlement of RSUs. The sale was mandated by the company’s “sell to cover” election and is described as non-discretionary for the executive.
Corbus Pharmaceuticals Holdings, Inc. director and Chief Executive Officer Yuval Cohen reported an open-market sale of 13,871 shares of common stock at a weighted average price of $7.7826 per share on February 13, 2026.
According to the disclosure, this sale was executed under a Rule 10b5-1 trading plan adopted on March 14, 2025 and was mandated as a “sell to cover” transaction to satisfy tax withholding obligations tied to the vesting and settlement of restricted stock units (RSUs), rather than a discretionary trade. Following this transaction, Cohen directly owned 174,316 shares, which includes 138,049 unvested RSUs subject to their existing vesting schedules.
A holder of Corbus Pharmaceuticals Holdings (symbol CRBP) common stock has filed a notice of proposed sale under Rule 144. The filing covers 20,000 shares of common stock, to be sold through Stifel Nicolaus & Company on the Nasdaq, with an aggregate market value of $812,600. These shares were acquired on February 13, 2026 as restricted stock units granted by the issuer as equity compensation, and became payable on the same date. The notice also confirms the seller states they are not aware of any undisclosed material adverse information about the issuer’s current or future operations.
Octagon Capital Advisors LP, Octagon Investments Master Fund LP, and Ting Jia report a 5.4% beneficial ownership stake in Corbus Pharmaceuticals Holdings, Inc. common stock, representing 955,000 shares. The shares are held by Octagon Investments Master Fund, with Octagon as investment manager and Jia as control person.
The reporting persons share voting and dispositive power over all 955,000 shares and certify that the position was acquired and is held in the ordinary course of business, not for the purpose of changing or influencing control of Corbus Pharmaceuticals.
Corbus Pharmaceuticals’ Chief Medical Officer Dominic Smethurst sold 3,285 shares of common stock on February 3, 2026 at a weighted average price of $8.0898 per share. The shares were sold to cover tax withholding triggered by the vesting and settlement of restricted stock units under an issuer-mandated “sell to cover” arrangement, so the sale was not discretionary. After this transaction, he beneficially owns 95,887 shares, including 86,265 unvested RSUs that remain subject to their vesting schedules.
Corbus Pharmaceuticals Holdings, Inc. Chief Operating Officer Ian Hodgson reported a mandated sale of common stock. On February 3, 2026, he sold 2,415 shares of Corbus common stock at a weighted average price of $8.0899 per share to cover tax withholding from vesting restricted stock units (RSUs).
The company required this "sell to cover" transaction for tax obligations, so it was not a discretionary trade by Hodgson. After the sale, he beneficially owned 51,927 shares, which includes 48,108 unvested RSUs that remain subject to their respective vesting schedules.
Corbus Pharmaceuticals Holdings, Inc.'s Chief Medical Officer, Dominic Smethurst, reported equity awards received on January 14, 2026. He was granted 28,365 restricted stock units (RSUs) that will settle in common shares, with 25% vesting on each of the first four anniversaries beginning January 14, 2027, and a pro rata acceleration feature if his service is terminated by the company without cause after the first vesting date. He also received an annual stock option award for 85,095 shares at an exercise price of $8.26 per share, vesting 25% on January 14, 2027 and the remaining 75% in equal monthly installments over 36 months starting February 14, 2027. Following these transactions, he beneficially owned 99,172 shares of common stock, including 93,065 unvested RSUs subject to their existing vesting schedules.